Skip to content
Genetic variants in African-American and Hispanic patients with breast cancer.
Dutta P, Keung MY, Wu Y, Vadgama JV.
Oncol Lett. 2022 Dec 16 [eCollection 2023 Feb];25(2):51. doi: 10.3892/ol.2022.13637.
Long-term risk of cancer among the first-degree relatives of epithelial ovarian cancer patients: A cohort study with 48 years of follow up.
Kotaniemi-Talonen L, Pukkala E, Aittomäki K, Auranen A.
Acta Obstet Gynecol Scand. 2023 Jan 16. doi: 10.1111/aogs.14504. Epub ahead of print.
Estimating copy number to determine BRCA2 deletion status and to expect prognosis in localized prostate cancer.
Nukaya T, Sumitomo M, Sugihara E, Takeda M, Nohara S, Tanishima S, Takenaka M, Zennami K, Takahara K, Shiroki R, Saya H.
Cancer Med. 2023 Jan 16. doi: 10.1002/cam4.5617. Epub ahead of print.
Factors that influence the management recommendations breast surgeons provide to women with pathogenic variants in moderate penetrance breast cancer susceptibility genes.
Vanderwal A, Lewis J, Basil J, Atzinger C, Widmeyer K.
J Genet Couns. 2023 Jan 15. doi: 10.1002/jgc4.1674. Epub ahead of print.
A case report of biallelic CHEK2 heterozygous variant presenting with breast cancer.
Soleimani T, Bourdon C, Davis J, Fortes T.
Clin Case Rep. 2023 Jan 11 [eCollection 2023 Jan];11(1):e6820. doi: 10.1002/ccr3.6820.
First-line Rucaparib Plus Bevacizumab Maintenance Completed One-Year in Germline BRCA1-Mutated Advanced Ovarian Cancer.
Roy S, Ghosh J, Ganguly S, Biswas B, Bhaumik J.
Cureus. 2022 Dec 13;14(12):e32493. doi: 10.7759/cureus.32493.
Post navigation